

Specialty Pharmacy

Effective July 1, 2017

Beginning July 1, 2017, specialty medications must be obtained from our designated specialty pharmacy, Accredo. Accredo has the capacity and expertise to effectively manage the coordination and distribution of specialty medications.

Accredo provides the following services:

- Safety programs that help prevent potentially harmful drug interactions
- Access to a team of pharmacists and nurses who have received specialized training
- Registered nurses available for in-home medication administration, when clinically appropriate and as the member's plan allows
- Scheduled delivery to members' home or their physicians' offices (where allowable by law) at no additional charge
- Refill reminder calls

To ensure specialty medications are filled through Accredo beginning July 1, Blue KC will notify providers, groups, and members who are currently filling their specialty medication at Walgreens Specialty Pharmacy. If the member chooses to continue filling the prescription at Walgreen Specialty Pharmacy, he or she will be responsible for the full cost of the medication. Blue KC will update the member contract limiting certain infused or injectable drugs to ensure they are only filled through Accredo. This change will become effective when the prescription drug's prior authorization expires.

Blue KC is encouraging members to request their providers obtain medications from Accredo as soon as possible to ensure coverage is not interrupted. Affected members will be notified of these changes by letter and a reminder call as the prior authorization expiration date for their medication nears. Once the current prior authorization has expired, the specialty medication must be obtained through Accredo.

Also, beginning July 1, 2017, the following specialty medications will require prior authorization:

- Actemra – tocilizumab
- Acthar – respiratory corticotropin
- Advate, Kogenate, Kovaltry, Recombinate – factor VIII
- Aldurazyme – laronidase
- Alphanate/VWF – factor VIII/VonWillebrand factor
- Alprolix – factor IX, Fc fusion protein
- Aralast, Prolastin, Zemaira – alpha 1 Proteinase Inhibitor
- Avastin – bevacizumab
- BeneFIX – factor IX
- Benlysta – belimumab
- Blincyto – blinatumomab
- Cerezyme – imiglucerase
- Cinryze – C1 inhibitor
- Elaprase – idursulfase
- Entyvio – vedolizumab
- Fabrazyme – agalsidae
- Feiba – anti-inhibitor Glassia – alpha 1 Proteinase Inhibitor
- Herceptin – trastuzumab
- Kalbitor – ecallantide
- Lemtrada – alemtuzumab

Continued

- Lumizyme – alglucosidase
- Mozobil – plerixafor
- NovoSeven - factor VIIa
- Orencia – abatacept
- Perjeta – pertuzumab
- Rituxan – rituximab
- Rixubis – factor IX

- Ruconest – C1 inhibitor
- Soliris – eculizuma
- Stelara – ustekinumab
- Synagis – palivizumab
- Vimizim – elosulfase
- Vpriv – velaglucerase
- Yervoy – ipilipumab